Sab bio announces positive topline phase 1 clinical results with potentially disease-modifying t1d therapy sab-142

Sab-142 was generally well-tolerated among healthy volunteers; data from phase 1 trial confirms sab-142 does not cause serum sickness or anti-drug antibodies at target dose study results support that sab-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetes results will be presented in an r&d webinar event today at 8:00 am et; registration details below miami, jan. 28, 2025 (globe newswire) -- sab bio (nasdaq:  sabs ), (“sab bio” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced positive topline data from a phase 1 trial of sab-142 in a single-ascending dose among healthy volunteers. the study met its primary objectives related to safety and pharmacodynamic activity enabling sab-142 to advance to phase 2b clinical development.
SABS Ratings Summary
SABS Quant Ranking